|
|
|
|
|
|
|
13.01.26 - 21:24
|
Senate publishes draft market structure bill with limits on stablecoin rewards: CNBC Crypto World (CNBC)
|
|
|
On today's episode of CNBC Crypto World, major cryptocurrencies trade higher after new data showed inflation was lower than expected in December. Plus, the Senate Banking Committee releases the full text of proposed market structure legislation ahead of its markup this week. And, Polygon Labs CEO Marc Boiron discusses the firm's acquisitions of crypto payments company Coinme and digital asset infrastructure provider Sequence in moves geared at expanding Polygon's footing in stablecoin payments....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 18:24
|
U.S. FDA grants Ipsen′s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults. IPN60340 is an investigational first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer. Breakthrough Therapy Designation is intended to expedite the development and review of medicines for serious or life-threatening conditions with evidence of a substantial clinical improvement. IPN60340 previously received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025....
|
|
|
|
|
|
|
|
|
13.01.26 - 18:03
|
IMPLANET Reports Full-Year 2025 Revenue of €12.5 Million, Up Sharply by +33% (Business Wire)
|
|
|
U.S. sales +49% in 2025 (+56% at constant exchange rates)
First deliveries of JAZZ® to China following CFDA approval, totaling €0.5 million
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its full-year 2025 revenue as well as its cash position as of December 31, 2025.
Ludovic Lastennet, CEO of IMPLANET, stated: “We delivered a very strong commercial performance in 2025, with revenue of €12.5 million, representing +33% growth compared with the same period last year, thereby confirming the relevance of the development model we have been implementing for the past two years. Building on six consecutive quarters of sustained growth, we are firmly confident in the outlook for the coming quarters. The strong momentum in implant sales, up +36% in the fourth quarter, has been driven...
|
|
|
13.01.26 - 18:03
|
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--#AstraZeneca--Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, expanding the companies' existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca's global oncology portfolio.
The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI's generative and agentic AI platform into AstraZeneca's oncology research and development organization, supporting efforts to accelerate clinical development, enhance biomarker discovery, and enable the next wave of data-driven decision-making across the pipeline.
“Oncology drug development is becoming more complex, more data-rich, and more time-sensitive, and our companies expect AI solutions that are not only powerful but truly deployable in global trials and clinical settings,” said Gabi Raia, Chief Commercial Officer of Modella AI. “By joining As...
|
|
|
|
|
|
|
13.01.26 - 17:27
|
Faron Pharmaceuticals Ltd: PDMR Dealing (Accesswire)
|
|
|
TURKU, FINLAND / ACCESS Newswire / January 13, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
